Edition:
United Kingdom

Baxter International Inc (BAX.N)

BAX.N on New York Stock Exchange

87.31USD
21 Aug 2019
Change (% chg)

$0.34 (+0.39%)
Prev Close
$86.97
Open
$87.40
Day's High
$87.74
Day's Low
$87.14
Volume
341,347
Avg. Vol
572,403
52-wk High
$88.38
52-wk Low
$61.06

Latest Key Developments (Source: Significant Developments)

Baxter Reports Second Quarter GAAP Earnings Per Share Of $0.66
Thursday, 25 Jul 2019 

July 25 (Reuters) - Baxter International Inc ::BAXTER REPORTS SECOND-QUARTER 2019 RESULTS.Q2 GAAP EARNINGS PER SHARE $0.66.Q2 EARNINGS PER SHARE ESTIMATE $0.81 -- REFINITIV IBES DATA.SEES Q3 2019 ADJUSTED EARNINGS PER SHARE $0.82 TO $0.84 FROM CONTINUING OPERATIONS EXCLUDING ITEMS.SEES FY 2019 ADJUSTED EARNINGS PER SHARE $3.34 TO $3.40 FROM CONTINUING OPERATIONS EXCLUDING ITEMS.SEES Q3 2019 GAAP EARNINGS PER SHARE $0.75 TO $0.78 FROM CONTINUING OPERATIONS.SEES FY 2019 GAAP EARNINGS PER SHARE $2.81 TO $2.89 FROM CONTINUING OPERATIONS.Q2 REVENUE $2.8 BILLION VERSUS REFINITIV IBES ESTIMATE OF $2.79 BILLION.BAXTER INTERNATIONAL - PLANS TO SCALE INVESTMENTS IN U.S. TO ALIGN WITH PROPOSED MODELS FROM CMS AND PATIENT AND MARKET DYNAMICS ACROSS ADOPTION CURVE.BAXTER INTERNATIONAL - INVESTMENTS ARE ANTICIPATED AT $500 MILLION IN POTENTIAL NEW U.S. FACILITIES & IN EXISTING SITES.BAXTER INTERNATIONAL - ANTICIPATES THE INVESTMENTS TO HELP ACCELERATE RENAL CARE GROWTH,CONTRIBUTE POSITIVELY TO CO'S PREVIOUS FINANCIAL COMMITMENTS.EXPECTS Q3 SALES GROWTH OF 3% TO 4% ON A REPORTED BASIS.BAXTER INTERNATIONAL - SEES FY SALES GROWTH OF 1% TO 2% ON A REPORTED BASIS, AND APPROXIMATELY 4% ON BOTH A CONSTANT CURRENCY AND OPERATIONAL BASIS.EXPECTS Q3 SALES TO GROW APPROXIMATELY 5% ON BOTH A CONSTANT CURRENCY AND OPERATIONAL BASIS.Q3 EARNINGS PER SHARE VIEW $0.86, REVENUE VIEW $2.84 BILLION -- REFINITIV IBES DATA.FY2019 EARNINGS PER SHARE VIEW $3.33, REVENUE VIEW $11.21 BILLION -- REFINITIV IBES DATA.  Full Article

Baxter Supports Advancing American Kidney Health Initiative
Wednesday, 10 Jul 2019 

July 10 (Reuters) - Baxter International Inc ::BAXTER SUPPORTS ADVANCING AMERICAN KIDNEY HEALTH INITIATIVE AND PLANS SIGNIFICANT U.S. INVESTMENT TO HELP DRIVE IMPLEMENTATION.BAXTER INTERNATIONAL INC - INVESTMENTS ARE EXPECTED TO BE MADE IN POTENTIAL NEW U.S. FACILITIES, AS WELL AS EXISTING SITES.BAXTER - TO MAKE INVESTMENTS TO SUPPORT IMPLEMENTATION OF AMERICAN KIDNEY HEALTH INITIATIVE, EXPECTED TO RESULT IN NEW U.S. MANUFACTURING CAPACITY.  Full Article

Baxter International Files For Offering Of €750 Million 0.400% Senior Notes Due 2024 - SEC Filing
Tuesday, 14 May 2019 

May 14 (Reuters) - Baxter International Inc ::BAXTER INTERNATIONAL INC FILES FOR OFFERING OF €750 MILLION 0.400% SENIOR NOTES DUE 2024 AND €750 MILLION 1.300% SENIOR NOTES DUE 2029 - SEC FILING.BAXTER INTERNATIONAL INC - 2024 NOTES WILL MATURE ON MAY 15, 2024 AND THE 2029 NOTES WILL MATURE ON MAY 15, 2029.BAXTER INTERNATIONAL INC - NOTES WILL BE ISSUED IN THE MINIMUM DENOMINATION OF €100,000, AND IN INTEGRAL MULTIPLES OF €1,000 IN EXCESS THEREOF..  Full Article

Baxter International Announced An Increase In Quarterly Cash Dividend, To A Rate Of $0.22 Per Share Of Common Stock
Tuesday, 7 May 2019 

May 7 (Reuters) - Baxter International Inc ::BAXTER INCREASES DIVIDEND AND DECLARES QUARTERLY DIVIDEND.BAXTER INTERNATIONAL INC - ANNOUNCED AN INCREASE IN COMPANY'S QUARTERLY CASH DIVIDEND, TO A RATE OF $0.22 PER SHARE OF COMMON STOCK..BAXTER INTERNATIONAL - NEW DIVIDEND REPRESENTS ABOUT 16% INCREASE OVER PREVIOUS QUARTERLY DIVIDEND RATE OF $0.19 PER SHARE.  Full Article

Baxter International Says CEO José Almeida's FY 2018 Compensation Was $15.6 Mln
Tuesday, 26 Mar 2019 

March 26 (Reuters) - Baxter International Inc ::BAXTER INTERNATIONAL INC SAYS CEO JOSÉ ALMEIDA'S FY 2018 TOTAL COMPENSATION WAS $15.6 MILLION VERSUS $14.9 MILLION IN FY 2017 - SEC FILING.BAXTER INTERNATIONAL INC SAYS RATIO OF CEO ANNUAL TOTAL COMPENSATION FOR 2018 TO ANNUAL TOTAL COMPENSATION OF EMPLOYEE IS 346 TO 1.  Full Article

Baxter And Biomérieux Collaborate On Identification And Treatment Of Acute Kidney Injury
Tuesday, 19 Mar 2019 

March 19 (Reuters) - BAXTER INTERNATIONAL INC ::BAXTER AND BIOMÉRIEUX ANNOUNCE COLLABORATION TO IMPROVE IDENTIFICATION AND TREATMENT OF ACUTE KIDNEY INJURY.  Full Article

Baxter International Q4 GAAP Earnings Per Share $0.66 From Continuing Operations
Thursday, 31 Jan 2019 

Jan 31 (Reuters) - Baxter International Inc ::BAXTER REPORTS 2018 FOURTH-QUARTER AND FULL-YEAR RESULTS.Q4 GAAP EARNINGS PER SHARE $0.66 FROM CONTINUING OPERATIONS.Q4 REVENUE $2.8 BILLION VERSUS REFINITIV IBES ESTIMATE OF $2.8 BILLION.Q4 EARNINGS PER SHARE ESTIMATE $0.73 -- REFINITIV IBES DATA.SEES Q1 2019 ADJUSTED EARNINGS PER SHARE $0.66 TO $0.68 FROM CONTINUING OPERATIONS EXCLUDING ITEMS.SEES FY 2019 ADJUSTED EARNINGS PER SHARE $3.22 TO $3.30 FROM CONTINUING OPERATIONS EXCLUDING ITEMS.Q4 ADJUSTED EARNINGS PER SHARE $0.78 FROM CONTINUING OPERATIONS.FOR FULL-YEAR 2019 EXPECTS SALES GROWTH OF 0 TO 1 PERCENT ON A REPORTED BASIS.FOR FIRST-QUARTER 2019 COMPANY EXPECTS SALES TO DECLINE ABOUT 3 PERCENT ON A REPORTED BASIS.  Full Article

Baxter Starts U.S. Clinical Trial For On-Demand Peritoneal Dialysis Solution System
Monday, 7 Jan 2019 

Jan 7 (Reuters) - Baxter International Inc ::BAXTER STARTS U.S. CLINICAL TRIAL FOR ON-DEMAND PERITONEAL DIALYSIS SOLUTION SYSTEM.BAXTER INTERNATIONAL INC - FOOD AND DRUG ADMINISTRATION (FDA) HAS INDICATED THAT COMPANY MAY PROCEED WITH PROSPECTIVE, MULTI-CENTER CLINICAL TRIAL..BAXTER - AFTER CONCLUSION OF TRIAL, STUDY REPORTING PROCESS, CO EXPECTS TO SUBMIT NDA FOR CONCENTRATES AND 510(K) FOR DEVICE TO FDA.  Full Article

UK's CMA Not To Refer Baxter-Hospira Deal To Phase II Probe
Friday, 4 Jan 2019 

Jan 4 (Reuters) - UK's CMA::UK'S CMA- CMA HAS DECIDED NOT TO REFER ACQUISITION BY BAXTER INTERNATIONAL. OF HOSPIRA UKS COMPOUNDING BUSINESS AND RELATED ASSETS. TO PHASE II.  Full Article

Third Point LLC Says On Dec 3, Sold Aggregate Of 8 Mln Shares Of Baxter International's Common Stock In Block Trade At $68.62 Per Share - SEC Filing
Tuesday, 4 Dec 2018 

Dec 4 (Reuters) - THIRD POINT LLC::THIRD POINT LLC SAYS ON DEC 3, SOLD AGGREGATE OF 8.0 MILLION SHARES OF BAXTER INTERNATIONAL'S COMMON STOCK IN BLOCK TRADE AT $68.62 PER SHARE - SEC FILING.  Full Article

UPDATE 1-Congress seeks briefing on potential threat to U.S. heparin supply

WASHINGTON, July 30 Leaders of the U.S. House Energy and Commerce Committee on Tuesday asked the Food and Drug Administration about the potential threat to the U.S. heparin supply due to the outbreak of African swine fever in China.